TEVA Teva Pharmaceutical Industries Ltd
Price (delayed)
$16.74
Market cap
$18.98B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.45
Enterprise value
$33.76B
Highlights
The debt has declined by 10% year-on-year and by 6% since the previous quarter
TEVA's revenue is up by 4.4% year-on-year
TEVA's quick ratio is down by 7% YoY but it is up by 2% from the previous quarter
The gross profit rose by 5% year-on-year but it has declined by 3.6% since the previous quarter
TEVA's net income has dropped by 193% year-on-year and by 71% since the previous quarter
Teva Pharmaceutical Industries's EPS has shrunk by 190% YoY and by 71% QoQ
Key stats
What are the main financial stats of TEVA
Market
Valuations
Earnings
Shares outstanding
1.13B
Market cap
$18.98B
Enterprise value
$33.76B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.53
Price to sales (P/S)
1.14
EV/EBIT
1,875.53
EV/EBITDA
31.35
EV/Sales
2.04
Revenue
$16.54B
Gross profit
$8.06B
Operating income
-$317M
Net income
-$1.64B
EBIT
$18M
EBITDA
$1.08B
Free cash flow
$749M
Per share
Balance sheet
Liquidity
EPS
-$1.45
EPS diluted
-$1.45
Free cash flow per share
$0.66
Book value per share
$4.74
Revenue per share
$14.63
TBVPS
$17.47
Total assets
$39.33B
Total liabilities
$33.61B
Debt
$18.08B
Equity
$5.37B
Working capital
-$244M
Debt to equity
3.36
Current ratio
0.98
Quick ratio
0.5
Net debt/EBITDA
13.72
Margins
Efficiency
Dividend
EBITDA margin
6.5%
Gross margin
48.7%
Net margin
-9.9%
Operating margin
-1.9%
Return on assets
-4%
Return on equity
-26.1%
Return on invested capital
0.1%
Return on capital employed
0.1%
Return on sales
0.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TEVA stock price
How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
-1.53%
1 week
3.02%
1 month
-23.28%
1 year
28.77%
YTD
-24.05%
QTD
-24.05%
Financial performance
How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$16.54B
Gross profit
$8.06B
Operating income
-$317M
Net income
-$1.64B
Gross margin
48.7%
Net margin
-9.9%
TEVA's net income has dropped by 193% year-on-year and by 71% since the previous quarter
TEVA's operating income has plunged by 183% YoY and by 169% from the previous quarter
The net margin has dropped by 183% year-on-year and by 74% since the previous quarter
The operating margin has shrunk by 179% YoY and by 170% QoQ
Growth
What is Teva Pharmaceutical Industries's growth rate over time
Valuation
What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
3.53
P/S
1.14
EV/EBIT
1,875.53
EV/EBITDA
31.35
EV/Sales
2.04
Teva Pharmaceutical Industries's EPS has shrunk by 190% YoY and by 71% QoQ
TEVA's price to book (P/B) is 121% higher than its 5-year quarterly average of 1.6 and 7% higher than its last 4 quarters average of 3.3
Teva Pharmaceutical Industries's equity has decreased by 28% YoY and by 11% QoQ
The P/S is 43% above the 5-year quarterly average of 0.8 but 5% below the last 4 quarters average of 1.2
TEVA's revenue is up by 4.4% year-on-year
Efficiency
How efficient is Teva Pharmaceutical Industries business performance
Teva Pharmaceutical Industries's return on sales has shrunk by 98% QoQ and by 97% YoY
The company's return on invested capital has shrunk by 97% QoQ and by 94% YoY
TEVA's ROE has plunged by 85% from the previous quarter
Teva Pharmaceutical Industries's return on assets has shrunk by 74% QoQ
Dividends
What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Teva Pharmaceutical Industries financials performed over time
The total assets is 17% greater than the total liabilities
Teva Pharmaceutical Industries's current ratio has increased by 10% QoQ but it has decreased by 3.9% YoY
The total assets is down by 10% year-on-year and by 6% since the previous quarter
Teva Pharmaceutical Industries's equity has decreased by 28% YoY and by 11% QoQ
TEVA's debt to equity is up by 25% YoY and by 6% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.